Want to see HK:3320 full AI Analyst Report?
Top Page
China Resources Pharmaceutical Group Ltd.
(3320)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$4.50
▼(-2.39% Downside)
Action:Reiterated
Date:05/03/26
The score is driven primarily by steady but low-margin financial performance and rising leverage risk, partially offset by solid cash generation. Technicals are a meaningful drag due to weak near-term momentum and price below the 20-day average. Valuation supports the stock with a low P/E and a moderate dividend yield.
Positive Factors
Integrated business model
Vertical integration across distribution, retail and manufacturing provides durable revenue diversification and operational synergies. Nationwide logistics and retail footprint support cross-selling, inventory management and resilience to single-segment shocks, strengthening mid-term cash flow stability and competitive position.
Negative Factors
Rising leverage
Material increase in debt-to-equity to ~1.83 raises structural financial risk. Higher leverage elevates interest burden and reduces strategic optionality, making the company more sensitive to credit conditions and margin pressure; this constraint can persist across multiple quarters and limit growth investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated business model
Vertical integration across distribution, retail and manufacturing provides durable revenue diversification and operational synergies. Nationwide logistics and retail footprint support cross-selling, inventory management and resilience to single-segment shocks, strengthening mid-term cash flow stability and competitive position.
Read all positive factors
China Resources Pharmaceutical Group Ltd. (3320) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$27.08B
Dividend Yield2.95%
Average Volume (3M)13.76M
Price to Earnings (P/E)6.1
Beta (1Y)0.77
Revenue Growth4.66%
EPS Growth20.76%
CountryHK
Employees85,600
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume13,454,154
30 Day Avg. Volume13,759,791
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.49
Price to Sales (P/S)0.09
P/FCF Ratio1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.82Price Target Upside47.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Resources Pharmaceutical Group Ltd. Business Overview & Revenue Model
Company Description
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segme...
How the Company Makes Money
The company primarily makes money through (1) pharmaceutical distribution: selling medicines and healthcare products to hospitals, clinics, and other healthcare institutions, generating revenue based on the value and volume of products distributed...
China Resources Pharmaceutical Group Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
52
Neutral
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 300.01B | 274.18B | 270.40B | 254.11B | 236.81B |
| Gross Profit | 49.53B | 43.30B | 42.18B | 39.13B | 35.38B |
| EBITDA | 17.70B | 15.45B | 15.43B | 15.47B | 11.95B |
| Net Income | 4.50B | 3.57B | 3.85B | 3.50B | 3.08B |
Balance Sheet | |||||
| Total Assets | 318.34B | 274.28B | 271.48B | 243.93B | 248.56B |
| Cash, Cash Equivalents and Short-Term Investments | 31.05B | 17.48B | 59.27B | 32.52B | 37.32B |
| Total Debt | 104.87B | 73.43B | 62.16B | 63.85B | 67.96B |
| Total Liabilities | 187.52B | 169.90B | 169.20B | 150.24B | 152.69B |
| Stockholders Equity | 57.26B | 51.34B | 50.60B | 49.56B | 50.98B |
Cash Flow | |||||
| Free Cash Flow | 18.83B | 14.55B | 12.42B | 7.54B | 8.32B |
| Operating Cash Flow | 22.78B | 17.55B | 15.55B | 10.90B | 11.22B |
| Investing Cash Flow | -11.20B | -8.89B | -2.07B | -3.30B | -8.83B |
| Financing Cash Flow | -12.19B | -16.84B | -4.07B | -9.00B | 5.31B |
China Resources Pharmaceutical Group Ltd. Technical Analysis
Negative
4.61
Price Trends
4.93
Negative
4.84
Negative
4.73
Negative
Market Momentum
-0.12
Positive
28.36
Positive
5.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3320, the sentiment is Negative. The current price of 4.61 is above the 20-day moving average (MA) of 4.56, below the 50-day MA of 4.93, and below the 200-day MA of 4.73, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 28.36 is Positive, neither overbought nor oversold. The STOCH value of 5.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3320.
China Resources Pharmaceutical Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$26.30B | 12.81 | 13.95% | 4.09% | 1.48% | -1.55% | |
63 Neutral | HK$24.22B | 14.09 | 8.65% | 2.26% | 10.00% | -7.54% | |
61 Neutral | HK$16.24B | 6.26 | 12.65% | 5.11% | -4.09% | -22.73% | |
58 Neutral | HK$27.08B | 6.07 | 7.98% | 2.95% | 4.66% | 20.76% | |
58 Neutral | HK$60.09B | 16.07 | 7.19% | 1.69% | 1.52% | 22.54% | |
56 Neutral | HK$35.17B | 10.86 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3320
China Resources Pharmaceutical Group Ltd.
4.31
-0.58
-11.84%
HK:3933
The United Laboratories International Holdings
8.23
-6.18
-42.91%
HK:0867
China Medical System Holdings
9.93
-1.77
-15.16%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
14.19
-2.22
-13.55%
HK:1513
Livzon Pharmaceutical Group
23.40
-4.33
-15.61%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
15.06
-1.50
-9.04%
China Resources Pharmaceutical Group Ltd. Corporate Events
China Resources Pharmaceutical Raises RMB2 Billion in Third Tranche of 2026 PRC Bonds
Jun 26, 2026
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group, has completed the public issuance of the third tranche of its 2026 corporate bonds in mainland China....
China Resources Pharmaceutical Wins Shareholder Backing for Dividend, Board and Capital Mandates
Jun 12, 2026
China Resources Pharmaceutical Group’s shareholders approved all resolutions at the 12 June 2026 annual general meeting, including adoption of the 2025 financial statements and a final dividend of RMB0.122 per share. Investors also backed th...
China Resources Pharmaceutical Wins Approval to Register Up to RMB5 Billion in Medium-Term Notes
May 29, 2026
China Resources Pharmaceutical Group said its wholly owned unit, China Resources Pharmaceutical Holdings, has obtained registration approval from China’s National Association of Financial Market Institutional Investors to issue up to RMB5 bi...
China Resources Pharmaceutical Sets Final 2025 Dividend Timetable
May 18, 2026
China Resources Pharmaceutical Group Limited has declared a final ordinary dividend of RMB 0.122 per share for the financial year ended 31 December 2025, with shareholders able to receive it in either Hong Kong dollars or renminbi. The default pay...
China Resources Pharmaceutical Sets AGM to Approve Dividend, Board Mandates and Share Buy-Back
May 18, 2026
China Resources Pharmaceutical Group Ltd. has called its annual general meeting for 12 June 2026 in Hong Kong to review the audited financial statements for the year ended 31 December 2025 and to seek shareholder approval for key corporate matters...
China Resources Pharma Discloses Subsidiary’s Unaudited Q1 2026 Results Linked to PRC Note Issuance
Apr 30, 2026
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group Company Limited, has published unaudited financial statements for the three months ended 31 March 2026...
China Resources Pharmaceutical Completes RMB1.4 Billion Second Tranche of 2026 Bonds in China
Apr 28, 2026
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group Company Limited, has completed the public issuance of the second tranche of its 2026 corporate bonds i...
China Resources Pharmaceutical Discloses Weaker Q1 2026 Unaudited Results at Boya Bio-Pharmaceutical
Apr 24, 2026
China Resources Pharmaceutical Group has disclosed unaudited first-quarter 2026 figures for its Shenzhen-listed subsidiary, China Resources Boya Bio-pharmaceutical, which it controls with around 41.79% of the voting rights. The announcement highli...
CR Pharmaceutical Subsidiary CR Sanjiu Posts Higher Q1 Revenue but Weaker Cash Flow
Apr 24, 2026
China Resources Pharmaceutical Group has reported the unaudited first-quarter 2026 financial performance of its 63.22%-owned subsidiary, China Resources Sanjiu Medical Pharmaceutical. CR Sanjiu posted revenue of RMB 8.13 billion, up from RMB 6.85...
China Resources Pharma Flagship KPC Swings to Q1 Loss on Slumping Revenue
Apr 24, 2026
China Resources Pharmaceutical Group has disclosed the unaudited first-quarter 2026 financial results of its subsidiary KPC Pharmaceuticals, which showed a sharp deterioration in performance. KPC’s revenue fell to RMB836.2 million from RMB1....
CR Double-Crane Posts Softer Q1 Earnings but Stronger Cash Position for 2026
Apr 24, 2026
China Resources Pharmaceutical Group has disclosed the unaudited first-quarter 2026 financial results of its Shanghai-listed subsidiary, China Resources Double-Crane, which remain subject to potential audit adjustments and do not represent the con...
CR Jiangzhong Q1 2026 Profit Rises on Strong Cash Flow Despite Revenue Dip
Apr 24, 2026
China Resources Jiangzhong Pharmaceutical Co., Ltd., a Shanghai-listed subsidiary effectively controlled by China Resources Pharmaceutical Group Ltd., reported unaudited first-quarter 2026 results prepared under PRC GAAP. The company remains well-...
China Resources Pharma Flags Higher Q1 Profit at Tasly but Warns on Cash Outflow and Limited Scope
Apr 24, 2026
China Resources Pharmaceutical has disclosed key first‑quarter 2026 figures from subsidiary Tasly Pharmaceutical, which reported unaudited revenue of RMB2.16 billion and net profit of RMB364.6 million, both higher than a year earlier. Tasly&...
China Resources Pharma Highlights Strong First-Quarter Performance at Dong-E-E-Jiao
Apr 24, 2026
China Resources Pharmaceutical Group has disclosed the latest unaudited quarterly figures of its controlled subsidiary Dong-E-E-Jiao, a Shenzhen-listed Chinese medicine producer, highlighting the unit’s growing scale and strong balance sheet...
China Resources Pharmaceutical Raises RMB1.5 Billion in First Tranche of 2026 Bonds
Apr 16, 2026
China Resources Pharmaceutical Group Limited has announced that its wholly owned subsidiary China Resources Pharmaceutical Holdings Company Limited has completed the public issuance of the first tranche of its 2026 corporate bonds in mainland Chin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.